anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Dorsal central wrist pain, often a consequence of peri-scapholunate ligament injury, can result in a decline in functional performance. There is a scarcity of clinical data evaluating the effectiveness of conservative management on peri-scapholunate ligament injury. Conservative management includes education, immobilization with orthotic devices, scapholunate-stabilizing muscle strengthening, and proprioception training. The identification of the ligamento-muscular reflex and scapholunate-stabilizing muscles formed the rationale for a rehabilitation training program. We have devised an innovative standardized 16-week treatment program for patients with dorsal central wrist pain associated with acute peri-SL ligament injury. We hypothesized that the program can effectively reduce dorsal wrist pain and improve functional performance.
MATERIALS AND METHODS: Recruited subjects underwent the 16-week home-based program, which included immobilization and rehabilitation exercises, to improve their wrist stability. Follow-up was arranged every 4 weeks for progress monitoring. The Short-Form 12 item questionnaire version 2, power grip, pinch grip, wrist range of motion, total performance score and total pain score when performing activities of daily living were used to evaluate the effectiveness of the program. An exercise adherence questionnaire was used to evaluate adherence to the home rehabilitation program.
RESULTS: Twenty-three subjects (26 wrists) completed the program. Pain on visual analog scale improved by 5.1 cm and total pain score improved from 14.4/20 to 19.5/20. Total performance score reached 39/40, which indicated near-normal wrist function. Power grip and pinch grip increased by 22.3% and 17.8%, respectively. The physical component scale of the Short-Form 12 item questionnaire showed significant improvement, while the mental component scale did not. Overall adherence was fair.
DISCUSSION: Conservative management, including immobilization and rehabilitation training, can provide significant clinical improvement in patients with dorsal central wrist pain associated with acute peri-scapholunate ligament injury.
CONCLUSION: Standardized wrist rehabilitation can be taken as a reference treatment modality. It is an evidence-based non-invasive treatment option for clinicians and therapists.
Insulin resistance is a pathophysiological component of type 2 diabetes, obesity and elevated blood pressure. Overall they are syndromes with multifactorial ethology and partly unclarified pathophysiology. Insulin resistance also occur in more seldom diseases with a more unified pathogenesis. Growth hormone deficiency (GHD) in adults with hypopituitarism is an example of one of those seldom diseases. Prolonged GHD is associated with abdominal overweight, dyslipidemia and increased cardiovascular morbidity. Besides, GHD-patients have decreased insulin sensitivity presumably secondary to the altered body composition. Long term effects of GH-substitution improves insulin sensitivity but it is well-known that subcutaneous administration of GH acute worsen insulin sensitivity in both muscles- and liver-tissue. Recently it has been reported that insulin resistance in patients with type 2 diabetes is associated with the induction of a signal protein called suppressor of cytokine signalling (SOCS). It´s interesting that GH also induces a stimulation of SOCS.
The present invention relates to systems and methods for ensuring quality of care services. After care is provided a confirmation is received. This may include a message regarding the care delivery from the provider. The confirmation and message may be conveyed to friends and family of the recipient. Location data from the provider, and feeds from the recipient's location are collected. Any lapses of care and emergencies based upon the location data and feeds are likewise identified. Identifying lapses of care and emergencies includes cross referencing length of time the provider spent at the recipient's location against tasks that were supposed to be performed at the location to determine if there is a discrepancy. Likewise, the time and location of the provider can be cross referenced against the confirmation to determine if there is a discrepancy. In some embodiments the feeds are also analyzed for trigger events.
Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
Methylin has a high potential for abuse and misuse. The use of Methylin exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methylin can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse and Dependence (9.2)]. Misuse and abuse of CNS stimulants, including Methylin, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing Methylin, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store Methylin in a safe place, preferably locked, and instruct patients to not give Methylin to anyone else. Throughout Methylin treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
A total of 15 (female) patients, between 31 and 70 years, who were systemically and periodontally healthy and applied to the periodontology clinic for treatment, were included in our study. Criteria for inclusion in the study are having ≥15 permanent teeth excluding third molars, not using any orthodontic appliance, not being pregnant or breastfeeding, not having any uncontrolled chronic and/or auto-immune disease, and not smoking.
A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
Patients diagnosed with GCA and/or PMR will be enrolled in this cohort. They will undergo a series of interventions including immunological profiling (cytokine profiling and immune cell phenotyping using flow cytometry, ELISA, 3'mRNA sequencing, high content analysis via a cell-based ex-vivo assay), and diagnostic imaging (MRI, OCTA including further ophthalmological assessment, vascular and transorbital ultrasound. Samples will be collected from patients at various stages of the disease (t=0, t=6, t=12, t=18 months, during flare-ups). Furthermore, TAB will be stained with a VAP-1 antibody to assess the expression and localization of VAP-1 in the arterial tissue.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed group of inventions relates to medicine. Claimed are methods of immune response regulation and reduction of inflammatory symptoms in mammal, with atopic dermatitis. For this purpose introduced is, at least, one medication of frost-resistant plant kiwi and, at least, one corticosteroid. In regulation of immune response in case of atopic dermatitis included is the following treatment period, during which carried out is monotherapy by medication of frost-resistant kiwi without introduction of corticosteroids. Also claimed is composition, which contains, at least, one medication of frost-resistant kiwi and, at least, one corticosteroid. Also claimed is product in form of animal forage, which contains claimed composition. Claimed group of inventions insure efficient regulation of immune response and reduction of inflammatory symptoms in case of atopic dermatitis due to synergetic effect of combination of medications of frost-resistant kiwi and corticosteroids, which makes it possible to reduce need in additional application of corticosteroids in treatment of said pathology and in future carry out monotherapy by medication of frost-resistant kiwi without reduction of treatment efficiency. ^ EFFECT: invention can be applied for regulation of immune response and reduction of , at least, one symptom of inflammation in mammal which has atopic dermatitis. ^ 35 dwg, 5 tbl, 8 ex
BACKGROUND: A subset of neutrophils isolated from the peripheral blood mononuclear cells (PBMC) layer has recently been described in cancer patients.
METHODS: Double-gradient centrifugation was used to separate the neutrophil subsets. Western blotting and immunohistochemical assays were performed to assess CCDC25 expression levels.
RESULTS: In this study, we found that low-density neutrophils (LDNs) were more highly enriched in metastatic hepatocellular carcinoma (HCC) patients than in non-metastatic HCC patients. We then showed a CD61+ LDNs subset, which displayed distinct functions and gene expression, when compared with high-density neutrophils (HDNs) and CD61- LDNs. Transcriptomic analysis revealed that the CD61+ LDNs were predominantly enhanced in the transcription of glycolysis and angiogenesis associated gene, HMGB1 associated gene and granulation protein gene. These CD61+ LDNs displayed a prominent ability to trigger metastasis, compared with HDNs and CD61- LDNs. Specifically, CD61+ LDN-derived HMGB1 protein increased the invasion of HCC cells by upregulating CCDC25. Mechanistically, the CD61+ LDN-derived HMGB1 protein enhanced the invasiveness of HCC cells and triggered their metastatic potential, which was mediated by TLR9-NF-κB-CCDC25 signaling. Blocking this signaling pathway reversed the invasion of the CD61+ LDN-induced HCC cells. In vivo, we consistently showed that CD61+ LDN-derived HMGB1 enhances HCC metastasis to the lungs.
CONCLUSIONS: Overall, our findings showed that a subset of CD61+ LDNs has pro-metastatic effects on HCC, and may be used to target HCC in the clinical setting.
Chronic hepatitis C virus (HCV) infection is characterized by a variety of extra-hepatic manifestations; peripheral neuropathy (PN) is one of the most common, especially when mixed cryoglobulinemia (MCG) is present. The prevalence and risk factors of HCV-related PN in the absence of MCG are largely unknown. We conducted a prospective, single-center study, examining the prevalence and reversibility of HCV-associated neuropathy in the absence of MCG. Nerve fiber density in the epidermis was evaluated through skin biopsy and electroneurography (ENG) before HCV-treatment initiation and 1 year post sustained virological remission (SVR). Forty HCV-infected individuals (nine HIV co-infected) with no other neuron-harming factors were included; four other HCV mono- and three HIV co-infected individuals were excluded due to presence of diabetes, B12 insufficiency, or neurotoxic drugs. Twelve consecutive controls with no neuron-harming conditions were also recruited; eight more were excluded due to meeting exclusion criteria. Four patients had ENG signs of polyneuropathy (two with HCV mono- and two with HIV co-infection), while seven more (five with HCV mono- and two with HIV co-infection) had signs of mono-neuropathy, leading to PN prevalences of 22.5% and 44% for mono- and co-infection, respectively (p value 0.179). The two patients with HCV mono-infection and polyneuropathy and the one with ulnar nerve damage showed ENG improvement 1 year post SVR. Regarding intraepidermal nerve density, HCV infection, irrespective of HIV co-infection, was correlated with a lower intraepidermal neuron density that improved 1 year post SVR (p value 0.0002 for HCV and 0.0326 for HCV/HIV co-infected patients). PN is common in HCV infection; successful eradication of HCV leads to PN improvement.
The recommended dosage of AKEEGA is 200 mg niraparib/1,000 mg abiraterone acetate orally once daily in combination with 10 mg prednisone daily until disease progression or unacceptable toxicity.

Patients receiving AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Take AKEEGA on an empty stomach. Do not eat food two hours before and one hour after taking AKEEGA. Swallow tablets whole with water. Do not break, crush, or chew tablets.

If a patient misses a dose, instruct patients to take the dose as soon as possible on the same day and resume their next dose at the normal schedule the following day.
BACKGROUND: Oxaliplatin (OXA) is a vital tool in the chemotherapy of gastric cancer (GC) patients. Circular RNAs (circRNAs) are a group of non-coding RNAs that have been associated with tumorigenesis. Nevertheless, the function of circRNAs in OXA resistance of GC is unknown.
METHODS: Circ_0006089/miR-217/NRP1 were elucidated through qRT-PCR in GC OXA-tolerant tissues and cell lines. OXA half-inhibitory concentration (IC50) was quantified by MTT assay. RNA pull-down and luciferase reporter tests were applied to characterize the interaction between circ_0006089 and miR-217, miR-217 and NRP1 in GC cells.
RESULTS: The findings disclosed that circ_0006089 and NRP1 was heightened whereas miR-217 was dramatically declined in OXA-tolerant GC tissues and cell lines. OXA resistance was reduced and the proliferation, migration and invasion ability of OXA cells were diminished after silencing circ_0006089. In addition, circ_0006089 raised OXA resistance by sponging miR-217. Further studies revealed that miR-217 bound to NRP1 and weakened OXA resistance. In addition, it was found that circ_0006089 accelerated GC progression and OXA resistance by upregulating NRP1 expression via sponging miR-217.
CONCLUSION: Circ_0006089 regulated OXA resistance in GC cells through miR-217/NRP1 axis, implying it was a promising biomarker for GC therapy.
This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: method of obtaining erythromycin tablets consists in the following: mixture of erythromycin and polyvinylpyrrolidone with molecular weight 100002000 with their weight ratio 1:0.125-2 is dissolved in ethanol. Ratio of alcohol and erythromycin and polyvinylpyrrolidone mixture constitutes 1:3-7. After that solution is introduced into device for granulate drying, solvent is removed at temperature 37-41C. To obtained mass with weight ratio of components 1:2-4 added is mixture of microcrystalline cellulose, starch, lactose, taken with weight ratio 1:2.5-3:6.5-7, respectively. Magnesium stearate is introduced into mixture in amount 2-3% of granulate weight and mixture is tabletted. ^ EFFECT: claimed method of obtaining erythromycin tablets allows to increase its bioavailability and antibacterial activity. ^ 1 dwg, 3 tbl, 2 ex
FIELD: medicine, dermatology, pharmacy. SUBSTANCE: invention relates to agents preventing the development of acne disease. Invention proposes the agent consisting of 40-70% an aqueous-spirituous tincture (extract) of fresh-water sponge of family Spongillidae. Invention proposes also method for prophylaxis of acne disease involving extraction of sponge biomass with 40-70% ethyl alcohol in the ratio raw : extractant = 1:(5-20) at the room temperature for 20-40 days. Use of agent results to skin pores opening, release of stomach and sebaceous gland ducts from excess of sebaceous and corneous mass, normalization of keratinization and cutaneous fat secretion processes. EFFECT: enhanced effectiveness of agent, improved method of preparing. 5 cl
In the treatment of tramadol overdosage, primary attention should be given to the reestablishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. 

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of Tramadol Hydrochloride Extended-Release could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.
PROBLEM TO BE SOLVED: To prepare a second agent for permanent wave, excellent in storage stability in viscosity and function, and esp. useful for straight permanent by including crosslinked poly(sodium acrylate) in a specific content. SOLUTION: This second agent for permanent wave which contains an oxidizing agent contains 0.5-10 wt.% crosslinked poly(sodium acrylate). The crosslinked poly(sodium acrylate) is expressed by the formula and is obtained by random crosslinking >=200 straight-chain polymer having 300-1,000 polymerization degree with a crosslinker such as tetraallyloxyethane. The oxidizing agent is pref. sodium bromate, hydrogen peroxide, etc., in the content of ca. 0.5-20 wt.%.
The utility model discloses a rheumatism sticking plaster capable of being pasted on a wounded skin surface. The rheumatism sticking plaster comprises a base fabric and a medicine layer coated on the lower surface of the base fabric. The rheumatism sticking plaster is characterized in that a plurality of holes are disposed in the base fabric. Each hole is covered by an independent patch. The medical layer is coated on the lower surface of each patch. The rheumatism sticking plaster has the most outstanding advantages that the rheumatism sticking plaster can be applied on the skin surface with a little trauma, and not only can have an analgesic effect but also can not hurt the trauma.
FIELD: stomatology and medicine adhesives. SUBSTANCE: proposed composition contains (mass parts): pH meter 25.0-45.0, powder on the base of fluoro-aluminosilicate glass 105.7-191.5, 2-hydroxyethyl methacrylate 21.0-41.0, photo initiator 3.0-6.0, water 25.0-47.0. Mentioned above pH meter is chosen of group which includes grafted copolymer of polyalkylene acid having side ethylene unsaturated groups, grafted copolymer of allyl isocyanate and polyalkylene acid. Adhesion of proposed composition and dentine is 99.5-104.5 kg/cm 2 , compressive strength is 53.2-67.5 MPa, tensile strength is 11.2-12.4 MPa. EFFECT: improves quality of desired product. 7 tbl
The invention discloses a fish liver hydrolysate, a preparation method and the application thereof. The preparation method of the hydrolysate is characterized in that: a liver is separated from the fish body of a skipjack, a tunny, an anglerfish, a ray, a sting ray, a sierra, a chub, a grass carp, a bighead carp or a mackerel, washed and then frittered or homogenized, and then is stirred at the temperature of 20-30 DEG C for 12-30h hydrolysis to obtain a hydrolysate; the hydrolystate is filtered or centrifuged at the speed of 700-1000 * g to collect clear solution, and then is lyophilized in vacuum. The hydrolysate of the skipjack liver can be used for preparing an active component of health products and relative pharmaceuticals which assists in lowering lipid, and treating fatty liver and hypertension, and the like; according to the requirements of health care and treatment, the fish liver hydrolysate liver can be prepared into a plurality of preparations together with edible and medicinal adjuvants. In the preparation method, the fish is taken as raw material; the liver is separated from the fish for hydrolysis to prepare the fish liver hydrolysate. The raw material adopted has rich sources and is available, and no exogenous enzyme is needed to be added. The method has the advantages of simple procedures, low equipment investment, no environmental pollution, and high productyield, which is suitable for industrialized production.
Clinical trials of fluticasone propionate/salmeterol DISKUS for asthma did not include sufficient numbers of subjects aged 65 years and older to determine whether older subjects with asthma respond differently than younger subjects. 

Of the total number of subjects in clinical trials receiving fluticasone propionate/salmeterol DISKUS for COPD, 1,621 were aged 65 years and older and 379 were aged 75 years and older. Subjects with COPD aged 65 years and older had a higher incidence of serious adverse events compared with subjects younger than 65 years. Although the distribution of adverse events was similar in the 2 age groups, subjects older than 65 years experienced more severe events. In two 1-year trials, the excess risk of pneumonia that was seen in subjects treated with fluticasone propionate/salmeterol DISKUS compared with those treated with salmeterol was greater in subjects older than 65 years than in subjects younger than 65 years [see Adverse Reactions (6.2)]. As with other products containing beta2-agonists, special caution should be observed when using Fluticasone Propionate/Salmeterol DISKUS in geriatric patients who have concomitant cardiovascular disease that could be adversely affected by beta2-agonists. Based on available data for fluticasone propionate/salmeterol DISKUS or its active components, no adjustment of dosage of Fluticasone Propionate/Salmeterol DISKUS in geriatric patients is warranted.

No relationship between fluticasone propionate systemic exposure and age was observed in 57 subjects with COPD (aged 40 to 82 years) given 250 or 500 mcg twice daily.
Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
The invention discloses an irbesartan hydrochlorothiazide tablet. The tablet is composed of irbesartan, hydrochlorothiazide, croscarmellose sodium, lactose, microcrystalline cellulose and magnesium stearate according to the mass ratio of (140-160):(11-14):(10-50):(10-33):(21-59):(2-3). The invention further provides a method for preparing the irbesartan hydrochlorothiazide tablet. According to the method, first the disintegrant croscarmellose sodium, irbesartan and lactose undergo joint wet granulation, are dried and then crushed and screened to obtain premix, and then the premix is mixed with hydrochlorothiazide and microcrystalline cellulose to undergo wet granulation again. The method enhances mobility and miscibility of irbesartan fines, and irbesartan is evenly mixed with hydrochlorothiazide more easily. The tablet has the advantages of being high in dissolution rate and uniformity.
The present invention relates to methods for laser surgery and growth factor stimulation for ultra-precision surgery with healing. The method is achieved by cutting biological tissue using an ultrafast laser, which produces laser pulses less than 10 picosecond in duration, to induce a cold ablation process in order to avoid the formation of carbonaceous or other materials that cannot be removed efficiently or completely from the wounded area through natural healing mechanisms. By use of femtosecond lasers, a negligible amount of debris is generated and an outer layer of intact but non viable cells are created principally through shock wave induce damage and ionizing radiation effects induced by multiphoton absorption of ultrashort laser pulses. The normal healing process is blocked by this outer layer of cells as all cell contacts are still intact. Therefore the healing process must be stimulated. The healing may be triggered or accelerated, or both, by application of growth factor molecules and/or signal proteins to the effectively undamaged cells causing the damaged cells to be replaced and the wound to close. The combination of very precise laser cutting used in combination with growth factors is the key to this unique tool.